Stereotactic ablative radiotherapy for the comprehensive treatment of 4–10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial

David A. Palma(Western University), Suresh Senan(Amsterdam Neuroscience), Sashendra Senthi(Alfred Health), Famke L. Schneiders(Amsterdam University Medical Centers), Glenn Bauman(Thomas Jefferson University Hospital), Stephen Harrow(Beatson West of Scotland Cancer Centre), Stewart Gaede(London Health Sciences Centre), George Rodrigues(London Health Sciences Centre), Liam Mulroy(Nova Scotia Cancer Centre), Alexander V. Louie(London Health Sciences Centre), Rohann Correa(London Health Sciences Centre), Mitchell Liu(Positive Living North), Tanja D. de Gruijl(Dutch Cancer Society), Michael Lock(London Health Sciences Centre), Brian Yaremko(London Health Sciences Centre), Ben J. Slotman(Vrije Universiteit Amsterdam), Anthony J. Chalmers(Beatson West of Scotland Cancer Centre), Alison L. Allan(London Health Sciences Centre), Belal Ahmad(London Health Sciences Centre), Robert Olson(BC Cancer Agency), Joanna Laba(London Health Sciences Centre), Andrew Warner(London Health Sciences Centre), Anand Swaminath(Juravinski Cancer Centre), Devin Schellenberg(Surrey Place Centre), Cornelis J.A. Haasbeek(University of Amsterdam)
BMC Cancer
August 19, 2019
Cited by 267


Related Papers